Tirzepatide leads near-term, Retatrutide targets Class III, Foundayo expands maintenance—see 2030 sales & $1,300 PT.
KCB Group PLC recorded KShs. 24.4 billion in pre-tax profit for the first quarter ending March 31, 2026, representing a 15.3% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results